



## Clinical trial results:

### A 52 WEEK, PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

#### Summary

EudraCT number	2013-002644-87
Trial protocol	FI GB NL NO ES IT BG
Global end of trial date	15 April 2016

#### Results information

Result version number	v1 (current)
This version publication date	23 April 2017
First version publication date	23 April 2017

#### Trial information

##### Trial identification

Sponsor protocol code	B1481021
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01968980
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., 001 800-718-1021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 February 2017
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	15 April 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate a superior Low density lipoprotein cholesterol (LDL-C) lowering effect of PF-04950615 150 milligram (mg) administered by the subcutaneous (SC) route every two weeks (Q2wks) compared to placebo, in subjects with heterozygous familial hypercholesterolemia (HeFH) and at high and very high risk of cardiovascular (CV) events receiving a maximally tolerated dose of statin therapy and whose LDL-C is  $\geq 70$  milligram per deciliter (mg/dL) (1.81 millimole per liter [mmol/L]).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	23 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 23
Country: Number of subjects enrolled	Canada: 57
Country: Number of subjects enrolled	Finland: 27
Country: Number of subjects enrolled	Italy: 28
Country: Number of subjects enrolled	Netherlands: 46
Country: Number of subjects enrolled	Norway: 23
Country: Number of subjects enrolled	Poland: 13
Country: Number of subjects enrolled	South Africa: 47
Country: Number of subjects enrolled	Spain: 40
Country: Number of subjects enrolled	United Kingdom: 23
Country: Number of subjects enrolled	United States: 43
Worldwide total number of subjects	370
EEA total number of subjects	223

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	292
From 65 to 84 years	78
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The subjects for the study were enrolled from 11 countries. The study start date was 23-Oct-2013 and the study completion date was 15-Apr-2016.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Subjects received placebo matched to PF-04950615 subcutaneous (SC) injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo matched to PF-04950615 once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

<b>Arm title</b>	PF--04950615
------------------	--------------

Arm description:

Subjects received PF-04950615 150 milligram (mg) SC injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Arm type	Experimental
Investigational medicinal product name	PF-04950615
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received PF-04950615 150 milligram (mg) once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

<b>Number of subjects in period 1</b>	Placebo	PF--04950615
Started	185	185
Completed	169	171
Not completed	16	14
Consent withdrawn by subject	13	5
Adverse Event	1	3
Other unspecified	1	2
Death	-	1
Does not meet entry criteria	1	3

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to PF-04950615 subcutaneous (SC) injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Reporting group title	PF--04950615
-----------------------	--------------

Reporting group description:

Subjects received PF-04950615 150 milligram (mg) SC injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Reporting group values	Placebo	PF--04950615	Total
Number of subjects	185	185	370
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	147	145	292
From 65-84 years	38	40	78
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	55.7	56.5	
standard deviation	± 11.2	± 10.5	-
Gender, Male/Female			
Units: Subjects			
Female	82	73	155
Male	103	112	215

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Subjects received placebo matched to PF-04950615 subcutaneous (SC) injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.	
Reporting group title	PF--04950615
Reporting group description: Subjects received PF-04950615 150 milligram (mg) SC injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.	

### Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12

End point title	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
End point description: Full analysis set (FAS) included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.	
End point type	Primary
End point timeframe: Baseline, Week 12	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	166		
Units: percent change				
arithmetic mean (standard deviation)	-0.3 (± 18.3)	-54.2 (± 29.34)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: LS-mean difference, associated 95 percent (%) confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	341
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	Mixed Model Repeated Measures (MMRM)
Parameter estimate	Least square (LS) mean difference
Point estimate	-54.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-59.5
upper limit	-49.5
Variability estimate	Standard error of the mean
Dispersion value	2.54

## Secondary: Percent Change From Baseline in Total Cholesterol (TC) at Week 12

End point title	Percent Change From Baseline in Total Cholesterol (TC) at Week 12
End point description: FAS included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	166		
Units: percent change				
arithmetic mean (standard deviation)	0 ( $\pm$ 14.45)	-37 ( $\pm$ 19.82)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: LS-mean difference, associated 95% confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	341
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-37.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-41.1
upper limit	-34.1



Variability estimate	Standard error of the mean
Dispersion value	1.77

### Secondary: Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12

End point title	Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12
End point description: FAS included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	166		
Units: percent change				
arithmetic mean (standard deviation)	0.4 (± 17.89)	-49.9 (± 26.8)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: LS-mean difference, associated 95% confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	341
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-51
Confidence interval	
level	95 %
sides	2-sided
lower limit	-55.7
upper limit	-46.4
Variability estimate	Standard error of the mean
Dispersion value	2.36

**Secondary: Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12**

End point title	Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 12
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	166		
Units: percent change				
arithmetic mean (standard deviation)	0.4 (± 15.96)	-47.5 (± 28.89)		

**Statistical analyses**

<b>Statistical analysis title</b>	Statistical Analysis 1
-----------------------------------	------------------------

Statistical analysis description:

LS-mean difference, associated 95% confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	341
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.8
upper limit	-43.2
Variability estimate	Standard error of the mean
Dispersion value	2.44

**Secondary: Percent Change From Baseline in Lipoprotein (a) at Week 12**

End point title	Percent Change From Baseline in Lipoprotein (a) at Week 12
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	172	166		
Units: percent change				
arithmetic mean (standard deviation)	2.2 ( $\pm$ 27.21)	-26.4 ( $\pm$ 23.63)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
-----------------------------------	------------------------

Statistical analysis description:

LS-mean difference, associated 95% confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	338
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	-28.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-33.9
upper limit	-23.2
Variability estimate	Standard error of the mean
Dispersion value	2.73

## Secondary: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12

End point title	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, "number of subjects analyzed" signifies those subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	175	166		
Units: percent change				
arithmetic mean (standard deviation)	-0.3 ( $\pm$ 12.99)	6.3 ( $\pm$ 15.11)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
LS-mean difference, associated 95% confidence intervals (CI), and p-values were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	341
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.001
Method	MMRM
Parameter estimate	LS mean difference
Point estimate	7
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.1
upper limit	9.9
Variability estimate	Standard error of the mean
Dispersion value	1.47

## Secondary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52

End point title	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =175, 173)	2.7 (± 25.38)	-50.1 (± 32.94)		
Week 52 (n =169, 171)	3.5 (± 21.49)	-45.3 (± 30.87)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS mean difference
Point estimate	-52.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-58.2
upper limit	-46
Variability estimate	Standard error of the mean
Dispersion value	3.1

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS mean difference
Point estimate	-48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-53.6
upper limit	-42.3

Variability estimate	Standard error of the mean
Dispersion value	2.87

## Secondary: Percent Change From Baseline in Total Cholesterol (TC) at Week 24 and 52

End point title	Percent Change From Baseline in Total Cholesterol (TC) at Week 24 and 52
End point description: FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe: Baseline, Week 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =176, 173)	1.6 (± 19.1)	-34.4 (± 21.44)		
Week 52 (n =169, 171)	1.2 (± 15.82)	-31 (± 21.5)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-35.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-40
upper limit	-31.6
Variability estimate	Standard error of the mean
Dispersion value	2.12

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description: Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-31.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-35.8
upper limit	-27.8
Variability estimate	Standard error of the mean
Dispersion value	2.02

### Secondary: Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 24 and 52

End point title	Percent Change From Baseline in Non High Density Lipoprotein Cholesterol (Non HDL-C) at Week 24 and 52
End point description: FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe: Baseline, Week 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =174, 173)	2.4 (± 24.06)	-46.7 (± 29.88)		
Week 52 (n =169, 171)	1.2 (± 19.25)	-41.8 (± 29.99)		

### Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-48.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-54.1
upper limit	-42.8
Variability estimate	Standard error of the mean
Dispersion value	2.86

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-42.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-47.5
upper limit	-36.9
Variability estimate	Standard error of the mean
Dispersion value	2.71

## Secondary: Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 and 52

End point title	Percent Change From Baseline in Apolipoprotein B (ApoB) at Week 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 24, 52	



<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =176, 171)	2.6 (± 19.29)	-44.8 (± 30.4)		
Week 52 (n =169, 171)	1.7 (± 16.45)	-39.3 (± 28.89)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-46.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-52.1
upper limit	-41.6
Variability estimate	Standard error of the mean
Dispersion value	2.67

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-40.5

Confidence interval	
level	95 %
sides	2-sided
lower limit	-45.5
upper limit	-35.5
Variability estimate	Standard error of the mean
Dispersion value	2.53

## Secondary: Percent Change From Baseline in Lipoprotein (a) at Week 24 and 52

End point title	Percent Change From Baseline in Lipoprotein (a) at Week 24 and 52
End point description: FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe: Baseline, Week 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =175, 172)	14.6 (± 157.93)	-21.2 (± 48.77)		
Week 52 (n =168, 171)	1.3 (± 30.5)	-15.1 (± 68.22)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-35.1

Confidence interval	
level	95 %
sides	2-sided
lower limit	-59.8
upper limit	-10.3
Variability estimate	Standard error of the mean
Dispersion value	12.58

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-15.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.3
upper limit	-4.4
Variability estimate	Standard error of the mean
Dispersion value	5.58

### Secondary: Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24 and 52

End point title	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
End point timeframe:	
Baseline, Week 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 24 (n =174, 173)	0.9 (± 14.19)	6.6 (± 12.85)		
Week 52 (n =169, 171)	2.2 (± 14.51)	4.7 (± 14.3)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	5.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.1
upper limit	8.7
Variability estimate	Standard error of the mean
Dispersion value	1.42

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	2.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1
upper limit	5.9
Variability estimate	Standard error of the mean
Dispersion value	1.53

## Secondary: Percent Change From Baseline in Triglycerides (TG) at Week 12, 24 and

End point title	Percent Change From Baseline in Triglycerides (TG) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =175, 166)	7.1 (± 41.23)	-8.7 (± 38.07)		
Week 24 (n =176, 173)	7.6 (± 51.97)	-9 (± 40.01)		
Week 52 (n =169, 171)	4.9 (± 33.03)	-3.4 (± 58.27)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.3
upper limit	-8.7
Variability estimate	Standard error of the mean
Dispersion value	4.22

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-17.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	-7.8
Variability estimate	Standard error of the mean
Dispersion value	4.9

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.4
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	5.04

<b>Secondary: Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52</b>	
End point title	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =175, 166)	-0.5 (± 11.7)	4.8 (± 12.15)		
Week 24 (n =176, 172)	-0.6 (± 10.69)	3.9 (± 10.72)		
Week 52 (n =169, 171)	0.3 (± 12.02)	3 (± 11.53)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	5.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.9
upper limit	7.8
Variability estimate	Standard error of the mean
Dispersion value	1.25

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	4.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.5
upper limit	6.8
Variability estimate	Standard error of the mean
Dispersion value	1.1

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	5.4
Variability estimate	Standard error of the mean
Dispersion value	1.22

### Secondary: Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =175, 166)	-2.6 (± 13.34)	-1.6 (± 15.68)		
Week 24 (n =175, 170)	-2.8 (± 11.88)	-1.8 (± 13.45)		
Week 52 (n =167, 171)	-3.5 (± 11.9)	-2.4 (± 14.5)		

### Statistical analyses



<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.3
upper limit	3.6
Variability estimate	Standard error of the mean
Dispersion value	1.5

<b>Statistical analysis title</b>	Statistical Analysis 3
Statistical analysis description:	
Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	3.6
Variability estimate	Standard error of the mean
Dispersion value	1.39

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615

Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	0.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	3.2
Variability estimate	Standard error of the mean
Dispersion value	1.31

### Secondary: Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Week 12, 24 and 52

End point title	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Week 12, 24 and 52
End point description:	FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.
End point type	Secondary
End point timeframe:	Baseline, Week 12, 24, 52

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percent change				
arithmetic mean (standard deviation)				
Week 12 (n =175, 166)	7.1 (± 41.23)	-8.7 (± 38.07)		
Week 24 (n =176, 173)	7.6 (± 51.97)	-9 (± 40.01)		
Week 52 (n =169, 171)	4.9 (± 33.03)	-3.4 (± 58.27)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.
Comparison groups	Placebo v PF--04950615

Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-25.3
upper limit	-8.7
Variability estimate	Standard error of the mean
Dispersion value	4.22

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-9.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.4
upper limit	0.4
Variability estimate	Standard error of the mean
Dispersion value	5.04

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-17.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-27
upper limit	-7.8

Variability estimate	Standard error of the mean
Dispersion value	4.9

## Secondary: Absolute Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12

End point title	Absolute Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12
End point description: FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe: Baseline, Week 12	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: milligram per deciliter (mg/dL)				
arithmetic mean (standard deviation)				
Baseline (n= 185, 185)	150 (± 59.75)	144.2 (± 41.96)		
Change at Week 12 (n= 175, 176)	-3 (± 30.47)	-79.1 (± 46.97)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-78.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-86.2
upper limit	-71.4
Variability estimate	Standard error of the mean
Dispersion value	3.75

---

**Secondary: Absolute Change From Baseline in Total Cholesterol (TC) at Week 12**

---

End point title	Absolute Change From Baseline in Total Cholesterol (TC) at Week 12
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

---

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n= 185, 185)	227.2 (± 67.31)	220.7 (± 46.26)		
Change at Week 12 (n= 175, 166)	-2.8 (± 36.43)	-83.2 (± 49.51)		

---

**Statistical analyses**

---

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
-------------------	------------------------

Number of subjects included in analysis	370
---	-----

Analysis specification	Pre-specified
------------------------	---------------

Analysis type	
---------------	--

Parameter estimate	LS Mean Difference
--------------------	--------------------

Point estimate	-83.2
----------------	-------

Confidence interval

level	95 %
-------	------

sides	2-sided
-------	---------

lower limit	-91.3
-------------	-------

upper limit	-75
-------------	-----

Variability estimate	Standard error of the mean
----------------------	----------------------------

Dispersion value	4.15
------------------	------

---

---

**Secondary: Absolute Change From Baseline in Non- High Density Lipoprotein**

---

## Cholesterol (Non HDL-C) at Week 12

End point title	Absolute Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non HDL-C) at Week 12
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n= 185, 185)	178.6 (± 66.64)	170.4 (± 45.12)		
Change at Week 12 (n= 175, 166)	-2.3 (± 36.24)	-86 (± 51.09)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-95.4
upper limit	-78.7
Variability estimate	Standard error of the mean
Dispersion value	4.25

## Secondary: Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12

End point title	Absolute Change From Baseline in Apolipoprotein B (ApoB) at Week 12
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at

specified time points for each arm, respectively.

End point type	Secondary
End point timeframe:	
Baseline, Week 12	

<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n= 185, 185)	115.9 (± 35.25)	112.8 (± 26.26)		
Change at Week 12 (n= 175, 166)	-0.9 (± 20.51)	-53.7 (± 33.07)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-53.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-59.2
upper limit	-48.5
Variability estimate	Standard error of the mean
Dispersion value	2.71

## Secondary: Absolute Change From Baseline in Lipoprotein (a) at Week 12

End point title	Absolute Change From Baseline in Lipoprotein (a) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n= 184, 185)	58.8 (± 69.88)	59.7 (± 63.38)		
Change at Week 12 (n= 172, 166)	-1.4 (± 14.02)	-14 (± 17.91)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-11.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.7
upper limit	-8.9
Variability estimate	Standard error of the mean
Dispersion value	1.47

## Secondary: Absolute Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12

End point title	Absolute Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12	



End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: mg/dL				
arithmetic mean (standard deviation)				
Baseline (n= 185, 185)	48.6 (± 11.84)	50.3 (± 11.4)		
Change at Week 12 (n= 175, 166)	-0.6 (± 6.31)	2.8 (± 7.89)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	2
upper limit	4.9
Variability estimate	Standard error of the mean
Dispersion value	0.75

## Secondary: Absolute Change From Baseline in Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC/HDL-C Ratio) at Week 12, 24 and 52

End point title	Absolute Change From Baseline in Ratio of Total Cholesterol to High Density Lipoprotein Cholesterol (TC/HDL-C Ratio) at Week 12, 24 and 52
End point description:	
FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.	
End point type	Secondary
End point timeframe:	
Baseline, Week 12, 24, 52	

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline (n =185, 185)	4.9 (± 1.81)	4.6 (± 1.32)		
Change at Week 12 (n =175, 166)	0 (± 1)	-1.8 (± 1.29)		
Change at Week 24 (n =174, 173)	0 (± 1.2)	-1.7 (± 1.29)		
Change at Week 52 (n =169, 171)	0 (± 1)	-1.5 (± 1.35)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description:	
Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.2
upper limit	-1.8
Variability estimate	Standard error of the mean
Dispersion value	0.12

Statistical analysis title	Statistical Analysis 2
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.1
upper limit	-1.6

Variability estimate	Standard error of the mean
Dispersion value	0.13

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-1.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.8
upper limit	-1.3
Variability estimate	Standard error of the mean
Dispersion value	0.12

### **Secondary: Absolute Change From Baseline in Ratio of Apolipoprotein B to Apolipoprotein A-I (ApoB/ApoA-I Ratio) at Week 12, 24 and 52**

End point title	Absolute Change From Baseline in Ratio of Apolipoprotein B to Apolipoprotein A-I (ApoB/ApoA-I Ratio) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12, 24, 52

<b>End point values</b>	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: ratio				
arithmetic mean (standard deviation)				
Baseline (n =185, 185)	0.8 (± 0.31)	0.8 (± 0.23)		
Change at Week 12 (n =175, 166)	0 (± 0.18)	-0.4 (± 0.25)		
Change at Week 24 (n =176, 171)	0 (± 0.17)	-0.4 (± 0.25)		
Change at Week 52 (n =169, 171)	0 (± 0.17)	-0.3 (± 0.25)		

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Statistical analysis description:	
Week 12: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	-0.4
Variability estimate	Standard error of the mean
Dispersion value	0.02

<b>Statistical analysis title</b>	Statistical Analysis 2
Statistical analysis description:	
Week 24: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group*visit interaction, baseline value, baseline value*visit interaction and geographical region.	
Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-0.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	-0.4
Variability estimate	Standard error of the mean
Dispersion value	0.02

<b>Statistical analysis title</b>	Statistical Analysis 3
-----------------------------------	------------------------

Statistical analysis description:

Week 52: LS-mean difference, associated 95% confidence intervals (CI) were derived from an MMRM model with fixed effects for treatment group, visit, treatment group\*visit interaction, baseline value, baseline value\*visit interaction and geographical region.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	LS Mean Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	-0.3
Variability estimate	Standard error of the mean
Dispersion value	0.02

**Secondary: Percentage of Subjects Achieving Low Density Lipoprotein-Cholesterol (LDL-C) Level Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (2.59 Millimoles per Liter) at Week 12, 24 and 52**

End point title	Percentage of Subjects Achieving Low Density Lipoprotein-Cholesterol (LDL-C) Level Less Than or Equal to ( $\leq$ ) 100 Milligram per Deciliter (2.59 Millimoles per Liter) at Week 12, 24 and 52
-----------------	---

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, 24, 52

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =175, 166)	13.1	83.1		
Week 24 (n =175, 173)	13.1	80.9		
Week 52 (n =169, 171)	16.6	70.8		

**Statistical analyses**

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Week 12: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed

effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	51.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	25.24
upper limit	106.1

---

**Statistical analysis title**

Statistical Analysis 2

Statistical analysis description:

Week 24: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	66.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	30.32
upper limit	147.43

---

**Statistical analysis title**

Statistical Analysis 3

Statistical analysis description:

Week 52: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	22.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	11.85
upper limit	44.01

**Secondary: Percentage of Subjects Achieving Low Density Lipoprotein-Cholesterol (LDL-C) Level Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (1.81 Millimoles per Liter) at Week 12, 24 and 52**

End point title	Percentage of Subjects Achieving Low Density Lipoprotein-Cholesterol (LDL-C) Level Less Than or Equal to ( $\leq$ ) 70 Milligram per Deciliter (1.81 Millimoles per Liter) at Week 12, 24 and 52
-----------------	--

End point description:

FAS included all subjects who were randomized. Here, 'n' signifies those subjects who were evaluable at specified time points for each arm, respectively.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, 24, 52

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: percentage of subjects				
number (not applicable)				
Week 12 (n =175, 166)	1.1	66.3		
Week 24 (n =175, 173)	1.1	60.7		
Week 52 (n =169, 171)	0.6	53.2		

**Statistical analyses**

Statistical analysis title	Statistical Analysis 1
----------------------------	------------------------

Statistical analysis description:

Week 12: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	200.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	47.16
upper limit	854.6

Statistical analysis title	Statistical Analysis 3
----------------------------	------------------------

Statistical analysis description:

Week 52: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	259.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	34.87
upper limit	1937.06

<b>Statistical analysis title</b>	Statistical Analysis 2
-----------------------------------	------------------------

Statistical analysis description:

Week 24: Odds ratio, associated 95% confidence interval from a Logistic Regression Model with fixed effects for treatment group,baseline value and geographical region was used for analysis.

Comparison groups	Placebo v PF--04950615
Number of subjects included in analysis	370
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Odds ratio (OR)
Point estimate	228
Confidence interval	
level	95 %
sides	2-sided
lower limit	51.95
upper limit	1000.39

## Secondary: Plasma PF-04950615 Concentrations at Week 12, 24 and 52

End point title	Plasma PF-04950615 Concentrations at Week 12, 24 and 52 <sup>[1]</sup>
-----------------	--

End point description:

Analysis was performed on all subjects who received at least 1 dose of PF-04950615. Here, 'n' signifies those subjects who were evaluable at specified time points.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 12, 24, 52

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: No statistical analysis was planned for this endpoint

<b>End point values</b>	PF--04950615			
Subject group type	Reporting group			
Number of subjects analysed	185			
Units: microgram per milliliter				
arithmetic mean (standard deviation)				
Week 12 (n =163)	6.23 (± 5.657)			



Week 24 (n =167)	7 ( $\pm$ 6.351)			
Week 52 (n =171)	4.84 ( $\pm$ 5.384)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Adverse Events Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions

End point title	Number of Subjects With Adverse Events Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions
-----------------	---

End point description:

Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthrititis, myalgia, polysynovitis, fever and if severe then included glomerulonephritis as well. Injection site reaction is a reaction at the site of the subcutaneous injection and characterized by the symptoms of erythema, swelling, tenderness and warmth. Subjects with any of the above type 1 or type 3 hypersensitivity reactions and subjects with any of the above injection site reactions were reported in this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to the end of study (up to 58 weeks)

End point values	Placebo	PF--04950615		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	185	185		
Units: subjects				
With Type 1 or 3 hypersensitivity reactions	0	0		
With Injection site reactions	1	38		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb)

End point title	Percentage of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb) <sup>[2]</sup>
-----------------	--

End point description:

Percentage of subjects with at least 1 positive ADA titer or 1 positive nAb titer were reported in this endpoint. ADA titer greater than or equal to ( $\geq$ ) 6.23 were considered as ADA positive and nAb titer level  $\geq$ 1.58 were considered as nAb positive. Analysis was performed on all subjects who received at least 1 dose of PF-04950615.

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline up to the end of study (up to 58 weeks)

---

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analysis was planned for this endpoint

<b>End point values</b>	PF--04950615			
Subject group type	Reporting group			
Number of subjects analysed	185			
Units: percentage of subjects				
number (not applicable)				
With positive ADA	49.7			
With positive nAb	33			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline up to the end of study (up to 58 weeks)

Adverse event reporting additional description:

The same event may appear as both an adverse event and a serious adverse event. However, what is presented are distinct events. An event may be categorized as serious in one subject and as non serious in another subject, or one subject may have experienced both a serious and non serious event during the study.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	PF--04950615
-----------------------	--------------

Reporting group description:

Subjects received PF-04950615 150 milligram (mg) SC injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to PF-04950615 subcutaneous (SC) injection once in every 2 weeks over a period of 52 weeks. Subjects were followed up to 58 weeks.

Serious adverse events	PF--04950615	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	24 / 185 (12.97%)	22 / 185 (11.89%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Appendix cancer			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder neoplasm			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung neoplasm malignant			

subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ovarian neoplasm			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatic carcinoma			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Peripheral ischaemia			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sudden cardiac death			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular stent restenosis			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Benign prostatic hyperplasia	Additional description: This is gender specific event. The number of participants evaluable for this event are 103 and 112.		

subjects affected / exposed <sup>[1]</sup>	1 / 112 (0.89%)	0 / 103 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea exertional			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychotic disorder			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Product issues			
Device breakage			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			

subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ankle fracture			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint dislocation			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lumbar vertebral fracture			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative ileus			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon rupture			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 185 (1.08%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina pectoris			

subjects affected / exposed	1 / 185 (0.54%)	3 / 185 (1.62%)	
occurrences causally related to treatment / all	0 / 2	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	1 / 185 (0.54%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial ischaemia			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Ischaemic stroke			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Migraine			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			

subjects affected / exposed	2 / 185 (1.08%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Retinal artery occlusion			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastritis erosive			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis acute			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			



subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Calculus bladder			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal colic			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Lumbar spinal stenosis			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			
subjects affected / exposed	0 / 185 (0.00%)	1 / 185 (0.54%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rotator cuff syndrome			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations Appendicitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 185 (0.00%) 0 / 0 0 / 0	1 / 185 (0.54%) 0 / 2 0 / 0	
Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 185 (0.54%) 0 / 1 0 / 0	0 / 185 (0.00%) 0 / 0 0 / 0	
Diverticulitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 185 (0.00%) 0 / 0 0 / 0	1 / 185 (0.54%) 0 / 1 0 / 0	
Gastroenteritis viral subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 185 (0.00%) 0 / 0 0 / 0	1 / 185 (0.54%) 0 / 1 0 / 0	
Lower respiratory tract infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 185 (0.00%) 0 / 0 0 / 0	1 / 185 (0.54%) 0 / 1 0 / 0	
Pulmonary tuberculosis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 185 (0.54%) 0 / 1 0 / 0	0 / 185 (0.00%) 0 / 0 0 / 0	
Pyelonephritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 185 (0.54%) 0 / 1 0 / 0	0 / 185 (0.00%) 0 / 0 0 / 0	
Wound sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 185 (0.00%) 0 / 0 0 / 0	1 / 185 (0.54%) 0 / 1 0 / 0	
Metabolism and nutrition disorders			

Obesity			
subjects affected / exposed	1 / 185 (0.54%)	0 / 185 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: This is gender specific event. The number of participants evaluable for this event are 103 and 112.

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	PF--04950615	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	70 / 185 (37.84%)	36 / 185 (19.46%)	
Nervous system disorders			
Headache			
subjects affected / exposed	10 / 185 (5.41%)	10 / 185 (5.41%)	
occurrences (all)	17	12	
General disorders and administration site conditions			
Injection site reaction			
subjects affected / exposed	38 / 185 (20.54%)	1 / 185 (0.54%)	
occurrences (all)	159	2	
Infections and infestations			
Influenza			
subjects affected / exposed	10 / 185 (5.41%)	6 / 185 (3.24%)	
occurrences (all)	11	6	
Nasopharyngitis			
subjects affected / exposed	15 / 185 (8.11%)	15 / 185 (8.11%)	
occurrences (all)	20	15	
Upper respiratory tract infection			
subjects affected / exposed	11 / 185 (5.95%)	7 / 185 (3.78%)	
occurrences (all)	14	9	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
21 July 2014	1. It was clarified that known history of cardiovascular disease (CVD) included any one of the examples of previous medical history, allowed inclusion of HeFH subjects with LDL-C $\geq 100$ mg/dL at the highest approved dose of statin or $\geq 110$ mg/dL not at the highest dose of statin without cardiovascular disease or risk equivalents. 2. Allowance for repeat LDL-C at the second screening visit if greater than 20% variance from initial visit was added. 3. The window for injection to 1 day before and 4 days after the scheduled date of injection was updated. 4. Injection sites to include upper abdominal quadrants were modified. 5. Follow up period for SAEs was updated to 40 days after last dose of study. 6. Protocol specified adverse events were removed. 7. There was a minor revision of adverse event reporting section of protocol in line with new Pfizer protocol template language.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported